Literature DB >> 115033

Effect of sulpiride on monoaminergic mechanisms in psychotic women.

L Bjerkenstedt, C Härnryd, G Sedval.   

Abstract

Concentrations of the major monoamine metabolites homovanillic acid (HVA) 4-hydroxy-3-methoxyphenylethylene glycol (MOPEG), and 5-hydroxyindoleacetic acid (5-HIAA) were determined in lumbar CSF of psychotic women with a schizophrenic symptomatology before and 4 weeks after treatment with sulpiride (Dogmatil 200 mg x 4). The metabolites were determined by a mass fragmentographic method. Prolactin concentrations in CSF and plasma were determined by radioimmunoassay. The clinical effects were evaluated by ratings according to the comprehensive psychopathology rating scale (CPRS) and a scale for side effects. Levels of HVA and prolactin in CSF and plasma were significantly elevated during treatment. No effects on concentrations of MOPEG or 5-HIAA were observed. The biochemical data indicate that clinical doses of sulpiride blocked dopamine receptors in the nigrostriatal pathway as well as in the tuberoinfundibular system. Treatment with sulpiride was associated with marked reductions in psychotic morbidity.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 115033     DOI: 10.1007/bf00496053

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  20 in total

1.  Correlation between plasma levels of prolactin and chlorpromazine in psychiatric patients.

Authors:  T Kolakowska; D H Wiles; A S McNeilly; M G Gelder
Journal:  Psychol Med       Date:  1975-05       Impact factor: 7.723

2.  Spectrophotofluorometric method for quantitative determination of sulpiride in human plasma and urine.

Authors:  T Kleimola; O Leppänen; J Kanto; R Mäntylä; E Syvälahti
Journal:  Ann Clin Res       Date:  1976-04

3.  Monoamine metabolite levels in cerebrospinal fluid of psychotic women treated with melperone or thiothixene.

Authors:  L Bjerkenstedt; B Gullberg; C Härnryd; G Sedvall
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1977-10-11

4.  Mass fragmentometric determination of homovanillic acid in lumbar cerebrospinal fluid of schizophrenic patients during treatment with antipsychotic drugs.

Authors:  G Sedvall; B Fyrö; H Nybäck; F A Wiesel; B Wode-Helgodt
Journal:  J Psychiatr Res       Date:  1974       Impact factor: 4.791

5.  Substituted benzamides as cerebral dopamine antagonists in rodents.

Authors:  P N Elliott; P Jenner; G Huizing; C D Marsden; R Miller
Journal:  Neuropharmacology       Date:  1977-05       Impact factor: 5.250

6.  Origins of catecholamine metabolites in monkey cerebrospinal fluid.

Authors:  E Gordon; M Perlow; J Oliver; M Ebert; I Kopin
Journal:  J Neurochem       Date:  1975-09       Impact factor: 5.372

7.  Regional effects of neuroleptics on dopamine metabolism and dopamine-sensitive adenylate cyclase activity.

Authors:  B Scatton; S Bischoff; J Dedek; J Korf
Journal:  Eur J Pharmacol       Date:  1977-08-15       Impact factor: 4.432

8.  Human prolactin: measurement in plasma by in vitro bioassay.

Authors:  D L Kleinberg; A G Frantz
Journal:  J Clin Invest       Date:  1971-08       Impact factor: 14.808

9.  Simultaneous determination of the three major monoamine metabolites in brain tissue and body fluids by a mass fragmentographic method.

Authors:  B Sandgárde; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1976-07-28       Impact factor: 4.530

10.  Stimulation of human prolactin secretion by sulpiride.

Authors:  Y Kato; S Ohgo; K Chihara; H Imura
Journal:  Endocrinol Jpn       Date:  1975-10
View more
  8 in total

1.  A clinical and pharmacodynamic evaluation of sulpiride.

Authors:  V A Rao; J Bailey; M Bishop; A Coppen
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

2.  Effects of chronic sultopride treatment on endocrine systems in psychotic women.

Authors:  Y Miyachi; A Mizuchi; H Hamano; K Sarai
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

3.  A randomized double blind group comparative study of sulpiride and amitriptyline in affective disorder.

Authors:  H M Standish-Barry; N Bouras; P K Bridges; J P Watson
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

4.  Sulpiride trial in chronic schizophrenia with comparison of two dosage regimens.

Authors:  D M Lewis; H R Bond; S H Curry
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

5.  3H-Flupenthixol binding in post-mortem brains of schizophrenics: evidence for a selective increase in dopamine D2 receptors.

Authors:  A J Cross; T J Crow; F Owen
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

6.  Sulpiride in tardive dyskinesia.

Authors:  D E Casey; J Gerlach; H Simmelsgaard
Journal:  Psychopharmacology (Berl)       Date:  1979       Impact factor: 4.530

7.  Prolactin response following intravenous and oral sulpiride in healthy human subjects in relation to sulpiride concentrations.

Authors:  F A Wiesel; G Alfredsson; M Ehrnebo; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

8.  Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment.

Authors:  G Alfredsson; F A Wiesel
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.